We picture pathologists behind the scenes, facing a microscope in a lab rather than a patient in a clinic. Although most patients may never even meet one, there may be no specialist more important to ensuring that the cancer treatment team delivers an effective regimen.
For generations, pathologists’ keen eyes and deep knowledge have been valuable sources of information for understanding a tumor. And today, pathologists have access to genomic information as well, making their role more up-front than ever. As we gain insight into how certain genomic alterations relate to treatment response, pathologists have had to become just as adept at interpreting genomic mutations as they are at identifying rare types of cancer.
Now, with innovations like targeted therapies and immunotherapies, genomics has become more vital than ever to understanding cancer. This topic will be front and center at this year’s College of American Pathologists (CAP) annual meeting, particularly as it relates to the immune checkpoint revolution in cancer treatment.
Certain markers have been identified which may correlate to treatment response. For example, PD-L1 expression level is currently being tested in a number of clinical trials as a marker to help predict responses to checkpoint inhibitor cancer immunotherapies.1 But just how useful this marker is still remains unclear. Several different assay types exist, and each has its own definition of PD-L1 positivity.2 Indeed, pathologists may disagree on which test is more accurate. Furthermore, PD-L1 is dynamically expressed on multiple types of cells, including immune cells as well as tumor cells.3 Together, these factors make it complicated to rely on PD-L1 as a predictive biomarker.
Tumor mutational burden (TMB) has emerged more recently as a quantitative marker that can help predict potential responses to immunotherapies across different cancers, including melanoma, lung cancer and bladder cancer.4,5,6 TMB is defined as the total number of mutations per coding area of a tumor genome. Importantly, TMB is consistently reproducible. It provides a quantitative measure that can be used to better inform treatment decisions, such as selection of targeted or immunotherapies or enrollment in clinical trials. You can learn more about TMB in our infographic here.
TMB is now included in the FoundationOne® comprehensive genomic profiling (CGP) test. Unlike hotspot testing, the FoundationOne® test uses massively parallel DNA sequencing to probe the entire coding sequence of the 300+ genes currently known to be altered in solid tumors. The comprehensive nature of this test also offers a practical option for molecular testing. It requires only a small tissue sample (8-10 slides) that can be taken from a previous biopsy while still providing results across a wide spectrum of genomic cancer drivers.
The addition of TMB to the FoundationOne® test represents a unique and important advance in our ability to navigate the emerging science of cancer immunotherapy. By adding this clinical marker that has a well-established relationship to treatment response.4,5,6 FoundationOne® can help pathologists unlock the full potential of precision medicine for cancer treatment.